Novel Antibody-Drug Conjugate May Improve PFS in Advanced Breast Cancer
SYD985 may provide a new treatment option for patients with previously treated locally advanced or metastatic HER2-positive metastatic breast cancer.
Breast Cancer
Ribociclib Improves Survival by More Than 1 Year in Advanced Breast Cancer
The overall survival benefit with ribociclib increased over time.
Adding Carboplatin to Neoadjuvant Chemo Improves EFS in Triple-Negative Breast Cancer
There was no significant difference in event-free survival between the carboplatin-containing arms.
Trastuzumab Deruxtecan: A New Standard for Second-Line Therapy in HER2+ Metastatic Breast Cancer?
Trastuzumab deruxtecan significantly improved progression-free survival.
Real-Time Mammography Reading Cuts Disparities in Diagnostic Imaging
Decrease in racial and ethnic disparities seen for same-day diagnostic imaging after abnormal screening mammograms
Presence of ctDNA Predicts Worse Outcomes in Early Breast Cancer
The presence of ctDNA, both at baseline and after treatment, was associated with worse survival outcomes.
Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Tecentriq Indication for Triple-Negative Breast Cancer Withdrawn
In 2019, the FDA granted accelerated approval to Tecentriq, a PD-L1 blocking antibody, for unresectable locally advanced or metastatic TNBC.
Model Predicts False-Positives in Breast Cancer MRI Screen
Full prediction model could prevent 45.5 percent of false-positive recalls, 21.3 percent of benign biopsies for those with extremely dense breasts
Genetic Testing Proposed for Women Diagnosed With Breast Cancer at Age 65+
Mutations in actionable breast cancer risk genes present in 3.2 percent of older women with breast cancer
